Immunic, Inc. Strengthens Its Board with Appointment of Simona Skerjanec

NEW YORK, July 24, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm developing oral therapies for chronic inflammatory and autoimmune diseases, announced the appointment of Simona Skerjanec to its board of directors. The appointment is effective July 22, 2024.

Ms. Skerjanec brings nearly three decades of pharmaceutical experience. She recently served as Senior Vice President, Global Head Neuroscience and Rare Diseases at Roche, where she led the commercial launch of the multiple sclerosis therapy Ocrevus®.

Duane Nash, Chairman of the Board of Directors of Immunic, expressed enthusiasm for Ms. Skerjanec's addition as the company approaches late-stage readouts for vidofludimus calcium in multiple sclerosis. Skerjanec’s experience in drug development and commercialization is expected to be a valuable asset.

Ms. Skerjanec stated she is eager to work with Immunic’s executive team, highlighting the potential of vidofludimus calcium to transform the treatment landscape for multiple sclerosis.